Abstract:Abstract Background/Aims Connective tissue diseases (CTD) are associated with several cardiovascular manifestations. Cardiovascular diseases (CVD) are significant cause of morbidity and premature death. The pathogenesis of CVD in CTD patients is incompletely understood and likely multifactorial. Traditional risk factors for atherosclerosis are common among patients with CTD as well as metabolic syndrome. Furthermore, diabetes, dyslipidaemia, hypertension, and obesity may all be exacerbated by connective tissue disease itself or treatment with glucocorticoids. The aim of this study was to assess the burden of CVD and the risk factors for the development of cardiovascular disease in patients with CTD. Methods This was a retrospective study from a single centre. We reviewed clinical records of CTD patients as determined by treating rheumatologist. This CTD cohort included patients with systemic lupus erythematosus (SLE), myositis, systemic sclerosis, Sjogren’s syndrome, mixed and undifferentiated connective tissue diseases. Data on demographic, clinical, laboratory parameters, cardiac investigations, treatment and outcome were collected from electronic patient records. CVD and traditional risk factors were defined using standard criteria. Results A total of 298 patients with CTD were included in the analysis. Mean age of the cohort was 61±17.7 years and majority were females (n = 240, 80.5%). Of the 298 patients, 64 had CVD (21.5%). Most common CVD was ischaemic heart disease (17 patients) followed by hypertension (12), arrhythmia (9), pulmonary arterial hypertension (7), valvular diseases (5), pericardial disease (3), cardiomyopathy (3), myocarditis (2), thromboembolism (3), aortic dissection (2) and coronary spasm (1). Patient with CTD who had CVD were older (72.5±12.2 years) compared to CTD patients who did not develop CVD (non-CVD group, 57.7±17.6 years). The duration of CTD was shorter in patients with CVD (88.9±41.7 months), compared to 106±84.3 months in non-CVD group. The risk factors such as smoking, diabetes and dyslipidaemia was higher in the CVD group. Comparing CVD vs non-CVD patients respectively, systolic BP (147.1±23.0 vs 133.6±18.3mmHg), diastolic BP (83.2 ± 16.3 vs 78.2 ± 11.2mmHg) and serum uric acid (321.8±97.4 vs 292±83.9mg/dL) values were higher and statistically significant (p < 0.05) in CVD group. Patients with CVD had longer exposure to steroids (50%) compared to non-CVD patients (31.6%). They required high dose steroids (9.4% vs 5.6% in non-CVD patients). Current and previous DMARD use was also higher in patients who had CVD (51.6% vs 44.9%). Conclusion This study has demonstrated high burden of cardiovascular disease in CTD patients. Traditional risk factors were more prevalent in the CVD group. DMARD’s and steroid use was also higher in the CVD group. Screening for cardiovascular diseases and disease control in CTD patients is paramount for better outcomes. Further analysis will be carried out for risk factors and relevant outcomes. Disclosure K.K. Garg: None. S. Sampath: None. A. Erinjogunola: None. B. Ting: None. H. Noori: None. G.M. Koduri: None.

Connective tissue disease as a challenge in heart failure: Three case reports

Successful Treatment of Systemic Sclerosis Complicated by Ventricular Tachycardia with a Cardiac Resynchronization Therapy-Defibrillator: A Case Report

[Analysis for clinical features of cardiovascular complication of diffuse connective tissue disease].

Cardiovascular disease in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis of observational studies

E012 Burden and risk factors for cardiovascular involvement in connective tissue disease

Abstract 399: End-stage Heart Failure Causes Severe Lung Fibrosis and Dysfunction

The role of immune cells in the pathogenesis of connective tissue diseases-associated pulmonary arterial hypertension

Pulmonary Hypertension Associated with Connective Tissue Disease

Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond "the usual suspects"

The Molecular Role of Immune Cells in Dilated Cardiomyopathy

Emerging Roles for Dendritic Cells in Heart Failure

Immune cells and related cytokines in dilated cardiomyopathy

COVID‐19 Infection in Patients with Connective Tissue Disease: A Multicity Study in Hubei Province, China

Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging

Overlap or mimic: Castleman disease and connective tissue disease

Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure

Integrative Analysis of Bulk and Single-Cell RNA Sequencing Data Reveals Cell Types Involved in Heart Failure

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease

Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction

The transition from hypertension to hypertensive heart disease and heart failure with preserved ejection fraction: a retrospective cross-sectional study of myocardial magnetic resonance strain and tissue characteristics

Myocarditis in connective tissue diseases: an often-overlooked clinical manifestation